Ki67 and cyclin A as prognostic factors in early breast cancer.: What are the optimal cut-off values?

被引:64
作者
Ahlin, C. [1 ]
Aaltonen, K.
Amini, R-M
Nevanlinna, H.
Fjallskog, M-L
Blomqvist, C.
机构
[1] Orebro Univ Hosp, Dept Oncol, S-70185 Orebro, Sweden
[2] Univ Uppsala Hosp, Dept Oncol, S-75185 Uppsala, Sweden
[3] Univ Uppsala Hosp, Dept Radiol, Uppsala, Sweden
[4] Univ Uppsala Hosp, Dept Clin Immunol, Uppsala, Sweden
[5] Univ Helsinki, Cent Hosp, Dept Oncol, Helsinki, Finland
[6] Univ Helsinki, Cent Hosp, Dept Obstet & Gynaecol, Helsinki, Finland
[7] Univ Uppsala Hosp, Dept Genet & Pathol, Uppsala, Sweden
关键词
breast cancer; cut-off value; cyclin A; Ki67; tissue microarray;
D O I
10.1111/j.1365-2559.2007.02798.x
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Aims: To find the optimal cut-off values for cyclin A and Ki67 in early breast cancer tumours and to evaluate their prognostic values. Methods and results: Tissue microarray (TMA) slides were constructed from 570 T1-4 N0-1 M0 breast cancer tumours. The TMA slides were stained for cyclin A and Ki67 using immunohistochemistry with commercial antibodies. To investigate the optimal cut-off values for cyclin A, Ki67 average and maximum values the material was split into two parts at cut-offs defined by dividing it into deciles. For each cut-off value the relative risk (RR) for metastasis-free survival (MFS) and overall survival (OS) was calculated comparing patients with high versus low cyclin A or Ki67 expression. When using a cut-off value around the seventh decile, cyclin A and Ki67 score correlated with the highest RR ratio for MFS in the chemotherapy-naive subgroup. Among patients having received adjuvant chemotherapy, no statistically significant differences in MFS or OS were found. Conclusions: The optimal cut-off value for cyclin A average is 8% and for cyclin A maximum value 11%; for Ki67 the corresponding values are 15% and 22%. Additional studies are needed to verify these results.
引用
收藏
页码:491 / 498
页数:8
相关论文
共 34 条
[1]   Reliability of cyclin A assessment on tissue microarrays in breast cancer compared to conventional histological slides [J].
Aaltonen, K. ;
Ahlin, C. ;
Amini, R-M ;
Salonen, L. ;
Fjallskog, M.-L. ;
Heikkila, P. ;
Nevanlinna, H. ;
Blomqvist, C. .
BRITISH JOURNAL OF CANCER, 2006, 94 (11) :1697-1702
[2]  
Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0
[3]   S-phase fraction combined with other patient and tumor characteristics for the prognosis of node-negative, estrogen-receptor-positive breast cancer [J].
Bryant, J ;
Fisher, B ;
Gündüz, N ;
Costantino, JP ;
Emir, B .
BREAST CANCER RESEARCH AND TREATMENT, 1998, 51 (03) :239-253
[4]   Overexpression of cyclin A overrides the effect of p53 alterations in breast cancer patients with long follow-up time [J].
Bukholm, IR ;
Husdal, A ;
Nesland, JM ;
Langerod, A ;
Bukholm, G .
BREAST CANCER RESEARCH AND TREATMENT, 2003, 80 (02) :199-206
[5]   Over-expression of cyclin A is highly associated with early relapse and reduced survival in patients with primary breast carcinomas [J].
Bukholm, IRK ;
Bukholm, G ;
Nesland, JM .
INTERNATIONAL JOURNAL OF CANCER, 2001, 93 (02) :283-287
[6]   The utility of mitotic index, oestrogen receptor and Ki-67 measurements in the creation of novel prognostic indices for node-negative breast cancer [J].
Clahsen, PC ;
van de Velde, CJH ;
Duval, C ;
Pallud, C ;
Mandard, AM ;
Delobelle-Deroide, A ;
van den Broek, L ;
van de Vijver, MJ .
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 1999, 25 (04) :356-363
[7]   Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? [J].
Colozza, M ;
Azambuja, E ;
Cardoso, F ;
Sotiriou, C ;
Larsimont, D ;
Piccart, MJ .
ANNALS OF ONCOLOGY, 2005, 16 (11) :1723-1739
[8]   Prognostic impact of proliferation associated factors MIBI (Ki-67) and S-phase in node-negative breast cancer [J].
Dettmar, P ;
Harbeck, N ;
Thomssen, C ;
Pache, L ;
Ziffer, P ;
Fizi, K ;
Janicke, F ;
Nathrath, W ;
Schmitt, M ;
Graeff, H ;
Hofler, H .
BRITISH JOURNAL OF CANCER, 1997, 75 (10) :1525-1533
[9]   Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families [J].
Eerola, H ;
Heikkilä, P ;
Tamminen, A ;
Aittomäki, K ;
Blomqvist, C ;
Nevanlinna, H .
BREAST CANCER RESEARCH, 2005, 7 (01) :R93-R100
[10]  
Elston C W, 2002, Histopathology, V41, P151